Aviva’s Mesa Laboratories MLAB Stock Holding History

Aviva’s Portfolio MLAB Stock Details MLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,861	Closed	-$1.18M	–	935
2021 Q1	$1.18M	Sell	4,861 -494	-9%	-$136K	0.01%	868
2020 Q4	$1.53M	Sell	5,355 -4,339	-45%	-$1.19M	0.01%	756
2020 Q3	$2.47M	Sell	9,694 -1,070	-10%	-$254K	0.01%	604
2020 Q2	$2.33M	Sell	10,764 -6,738	-38%	-$1.55M	0.01%	641
2020 Q1	$3.96M	Buy	+17,502	New	+$4.32M	0.03%	464

Other funds holding MLAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Aviva's MLAB Position: Q2 2021 in Review

Aviva sold out of Mesa Laboratories (MLAB) in Q2 2021, closing a stake of 4,861 shares — an estimated $1.18M sold.

Aviva first reported a position in MLAB in Q1 2020 and held it in 5 quarters. The position peaked at $3.96M in Q1 2020. 159 funds tracked by Wall St. Rank hold MLAB as of Q2 2021.

Aviva reported no remaining Mesa Laboratories position as of Q2 2021 after selling out during the quarter.
Aviva sold 4,861 Mesa Laboratories shares in Q2 2021, an estimated $1.18M.
Aviva first reported a position in Mesa Laboratories in Q1 2020 and held it in 5 quarters.
Aviva's Mesa Laboratories position peaked at $3.96M in Q1 2020.
159 funds tracked by Wall St. Rank held Mesa Laboratories as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.